ACKNOWLEDGMENTS
WEST, DENGUE
We sincerely thank the trial participants and their parents/guardians who agreed to take part in the trial, the data monitoring committee, the Dengue Case Adjudication Committee members, the Takeda expanded study team, the study team at PPD, and all the trial staff in each of the countries. We also acknowledge the contribution of the late Dan Stinchcomb and Inviragen, Inc. (Fort Collins, CO), in the initial developmental work of TAK-003 (Inviragen, Inc., was subsequently acquired by Takeda). We are grateful to Jenny Engelmoer (Sula Communications, Utrecht, Netherlands) and Miranda Dixon (Excel Medical Affairs, Horsham, West Sussex, UK) for editorial assistance in the preparation of this manuscript. The authors confirm that all ongoing and related trials for this drug/intervention are registered (#NCT02747927). This trial is registered at 